Alpelisib plus fulvestrant in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A

被引：2
|
作者：
Ciruelos, Eva M.
Lerebours, Florence
Rugo, Hope S.
Ruiz-Borrego, Manuel
Drullinsky, Pamela
Prat, Aleix
Bachelot, Thomas
Neven, Patrick
Park, Yeon Hee
Turner, Nicholas
Juric, Dejan
Gu, Ennan
Arce, Christina H.
Akdere, Murat
Chia, Stephen
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-P1-18-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-03
引用
收藏
页数：3
相关论文
共 50 条
  • [21] CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS (CDK4/6I) IN HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED/METASTATIC BREAST CANCER (A/MBC): A SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES
    Harbeck, N.
    Bartlett, M.
    Spurden, D.
    Hooper, B.
    Zhan, L.
    Rosta, E.
    Cameron, C.
    Mitra, D.
    Zhou, A.
    VALUE IN HEALTH, 2020, 23 : S27 - S27
  • [22] A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1
    Rugo, Hope S.
    Andre, Fabrice
    Rubovszky, Gabor
    Kaufman, Bella
    Inoue, Kenichi
    Takahashi, Masato
    Shimizu, Satoru
    Ciruelos, Eva M.
    Campone, Mario
    Conte, Pier Franco
    Iwata, Hiroji
    Loibl, Sibylle
    Mayer, Ingrid A.
    Juric, Dejan
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Sellami, Dalila B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) plus fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC)
    Burnette, S.
    Poehlein, E.
    Lee, H-J.
    Force, J.
    Westbrook, K.
    Moore, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S470 - S470
  • [24] Expert consensus recommendations for managing hyperglycemia and rash in patients with PK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with alpelisib (ALP)
    Gallagher, Emily J.
    Moore, Heather
    Lacouture, Mario E.
    Dent, Susan Faye
    Farooki, Azeez
    Goncalves, Marcus D.
    Isaacs, Claudine
    Johnston, Abigail
    Juric, Dejan
    Quandt, Zoe
    Spring, Laura
    Berman, Brian
    Decker, Melanie
    Hortobagyi, Gabriel N.
    Kaffenberger, Benjamin
    Kwong, Bernice Y.
    Pluard, Timothy J.
    Rao, Ruta D.
    Schwartzberg, Lee S.
    Broder, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 422 - 422
  • [25] Ribociclib (RIB) plus fulvestrant (FUL) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses
    Neven, P.
    Petrakova, K.
    Bianchi, G. V.
    Merino, L. De la Cruz
    Jerusalem, G.
    Beck, J. T.
    Sonke, G. S.
    Chia, S.
    Brucker, S.
    Wang, Y.
    He, W.
    Lorenc, K. Rodriguez
    Su, F.
    Im, S-A.
    ANNALS OF ONCOLOGY, 2018, 29 : 113 - +
  • [26] Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) plus fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
    Andre, F.
    Rugo, H. S.
    Juric, D.
    Rubovsky, G.
    Yamashita, T.
    Stemmer, S. M.
    Lu, Y- S.
    Miller, M. K.
    Lorenzo, I.
    Hu, H.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S498 - S499
  • [27] Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR plus ) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review
    Zhu, Linhui
    Wang, Mengmeng
    Luo, Xin
    Li, Huan
    Shan, Han
    Du, Qiong
    Zhai, Qing
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (04)
  • [28] A phase III study of alpelisib and fulvestrant for hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
    Iwata, H.
    Rubovszky, G.
    Loibl, S.
    Ciruelos, E.
    Campone, M.
    Juric, D.
    Rugo, H.
    Mayer, I.
    Conte, P. F.
    Kaufman, B.
    Inoue, K.
    Tesch, H.
    Li, Y-S.
    Mingorance, I. D.
    Ryvo, L.
    Iwase, H.
    Longin, A-S.
    Mills, D.
    Wilke, C.
    Andre, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Response evaluation with 18F FDG PET CT in hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (HR+/HER2-) advanced metastatic breast cancer (mBC) treated with cyclin-dependent kinase 4 and 6 (CDK4/6)inhibitors plus endocrine treatment
    Kumar, Arun
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [30] PIK3CA registry: A noninterventional, descriptive, retrospective cohort study of PIK3CA mutations in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
    Rajadurai, Pathmanathan
    Semiglazova, Tatiana
    Hegmane, Alinta
    El Karak, Fadi
    Chiu, Joanne W.
    Gupta, Sudeep
    Azim, Hamdy A.
    Kitzen, Josef Jem
    Arnaud, Antoine
    Haftchenary, Sina
    Wu, Jiwen
    Menon-Singh, Lakshmi
    Smith, LaTonya
    Zhukova, Lyudmila
    CANCER RESEARCH, 2022, 82 (04)
12345